Welcome to the monthly bonus episode of the AJ Bell Money & Markets podcast all about investment trusts, presented by Dan Coatsworth and Hannah Williford. The pair discuss the outlook for activist investors in the investment trust space, the extent to which Saba is involved in the industry, and who could be the next targets. [02:05] Dan talks to Ed Cartright, CEO of Arcus Investment, about a desire to replace the manager at Baillie Gifford Shin Nippon and take over running the trust. [15:13] This episode’s big theme is the healthcare space [25:37]. Dan talks to Gareth Powell from Polar Capital Global Healthcare Trust about why the sector disappointed for several years and has now burst back to life; as well as the underappreciated importance of generic drugs. Martin Gamble talks to Oliver Kenyon from RTW Investments about why big drug companies are buying small biotech firms. Dan also chats to Trevor Polishchuk from Worldwide Healthcare on how pharma companies have effectively been forced to invest heavily in the US to avoid tariffs; why Donald Trump has launched a website so consumers can buy medicines direct from manufacturers; and the outlook for drug pricing globally. Finally, Hannah interviews Carlos Hardenberg from the Mobius Investment Trust about dealing with political turmoil in emerging markets, and how he safeguards his investments from it. [49:37] Download AJ Bell’s free report on activists in the investment trust space: https://www.ajbell.co.uk/investment/investment-trust-report

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related